Mechanisms Of Action Of Gepants And Lasmiditan In Migraine Therapy

by

Migraine is a neurological condition characterized by intense, throbbing headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. Advances in migraine therapy have led to the development of targeted medications such as gepants and lasmiditan, which offer new options for patients who do not respond well to traditional treatments.

Overview of Migraine Pathophysiology

Understanding the mechanisms behind migraine is essential to appreciate how gepants and lasmiditan work. Migraines involve complex interactions between neural, vascular, and inflammatory pathways. Activation of trigeminal nerves leads to the release of vasoactive neuropeptides, causing vasodilation and inflammation that contribute to pain.

Gepants are a class of drugs that target the calcitonin gene-related peptide (CGRP) pathway, which plays a central role in migraine pathogenesis. By blocking CGRP receptors, gepants inhibit the neuropeptide’s ability to induce vasodilation and neurogenic inflammation.

Mechanism of Action of Gepants

Gepants bind selectively to CGRP receptors on blood vessels and nerve terminals. This prevents CGRP from activating its receptors, thereby reducing vasodilation and neurogenic inflammation that lead to migraine pain. This mechanism helps to alleviate both the pain and associated symptoms.

Lasmiditan: Serotonin (5-HT1F) Receptor Agonist

Lasmiditan is a selective serotonin receptor agonist that targets the 5-HT1F receptor subtype. Unlike triptans, which act on multiple 5-HT receptors, lasmiditan’s selectivity offers a different mechanism with potentially fewer vascular side effects.

Mechanism of Action of Lasmiditan

Lasmiditan activates the 5-HT1F receptors located on trigeminal nerve endings and in the central nervous system. This activation inhibits the release of neuropeptides like CGRP and substance P, reducing neurogenic inflammation and pain transmission. Additionally, lasmiditan’s central action helps modulate pain perception without causing vasoconstriction.

Comparison of Gepants and Lasmiditan

  • Target receptors: Gepants target CGRP receptors; lasmiditan targets 5-HT1F receptors.
  • Vascular effects: Gepants primarily reduce vasodilation; lasmiditan does not cause vasoconstriction.
  • Side effect profile: Lasmiditan may cause dizziness and sedation; gepants generally have fewer central nervous system side effects.
  • Use in patients: Both are suitable for acute migraine treatment, especially in patients with cardiovascular risk factors.

Conclusion

Gepants and lasmiditan represent targeted therapies that address different aspects of migraine pathophysiology. Gepants inhibit vasodilation by blocking CGRP receptors, while lasmiditan modulates pain transmission through serotonin receptor activation. Their development marks a significant advancement in personalized migraine management.